NCT02075619.

Methods	Open‐label, single‐centre, randomised, single‐dose, three‐way cross‐over, six‐sequence study
Participants	Male or female 21‐65 years of age inclusive, at the time of signing the informed consent Alanine transaminase, alkaline phosphatase and total bilirubin <= 1.5 x upper limit of normal (ULN) (isolated bilirubin > 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) Normal electrocardiogram (ECG) morphology and measurements. Single corrected QT interval (QTc) < 450 ms. In particular QTc < 450 msec or QT < 480 ms in subjects with Bundle Branch Block based on an average from three ECGs obtained over a brief recording period Female participants eligible if of non‐childbearing potential. Female participants must agree to use contraception until 14 days after last dose of amlodipine/rosuvastatin, i.e. after single dose of treatment period 3 Male participants with female partners of child‐bearing potential must agree to use one of the contraceptive methods and not to donate sperm. Chinese or white self‐reported by the participants for both parents and all 4 grandparents. The ethnic group is as defined by National Registration Identity Cards provided additional confirmation of ethnicity
Interventions	Experimental: Sequence 1 Four participants (2 Chinese and 2 white) will receive 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet in Period 1; 1 GSK3074477 fixed‐dose combination (FDC) formulation‐1 tablet in Period 2 and 1 GSK3074477 FDC formulation‐2 tablet in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a washout period of between 12‐17 days Experimental: Sequence 2 Four participants (2 Chinese and 2 white) will receive 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet in Period 1; 1 GSK3074477 FDC formulation‐2 tablet in Period 2 and 1 GSK3074477 FDC formulation‐1 tablet in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a washout period of between 12‐17 days Experimental: Sequence 3 Four participants (2 Chinese and 2 white) will receive 1 GSK3074477 FDC formulation‐1 tablet in Period 1, 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet in Period 2; and 1 GSK3074477 FDC formulation‐2 tablet in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a washout period of between 12‐17 days Experimental: Sequence 4 Four participants (2 Chinese and 2 white) will receive 1 GSK3074477 FDC formulation‐1 tablet in Period 1; 1 GSK3074477 FDC formulation‐2 tablet in Period 2; and 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a washout period of between 12‐17 days Experimental: Sequence 5 Four participants (2 Chinese and 2 white) will receive 1 GSK3074477 FDC formulation‐2 tablet in Period 1; 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet in Period 2; and 1 GSK3074477 FDC formulation‐1 tablet in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a washout period of between 12‐17 days Experimental: Sequence 6 Four participants (2 Chinese and 2 white) will receive 1 GSK3074477 FDC formulation‐2 tablet in Period 1; 1 GSK3074477 FDC formulation‐1 tablet in Period 2; and 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a washout period of between 12‐17 days
Outcomes	Primary outcomes: Plasma pharmacokinetics (PK) parameters of amlodipine and rosuvastatin following single dose administration Secondary outcomes: Safety as assessed by adverse events Safety as assessed by vital signs Safety as assessed by clinical laboratory safety data Safety as assessed by Electrocardiogram (ECG) parameters
Notes